{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:14:24Z","timestamp":1792134864576,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005625","name":"RSNA Research and Education Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["CAAA501A0US05T"],"award-info":[{"award-number":["CAAA501A0US05T"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Multiple approaches with [\n                    <jats:sup>68<\/jats:sup>\n                    Ga]-DOTATATE, a somatostatin analog PET radiotracer, have demonstrated clinical utility in evaluation of meningioma but have not been compared directly. Our purpose was to compare diagnostic performance of different approaches to quantitative brain [\n                    <jats:sup>68<\/jats:sup>\n                    Ga]-DOTATATE PET\/MRI analysis in patients with suspected meningioma recurrence and to establish the optimal diagnostic threshold for each method. Patients with suspected meningioma were imaged prospectively with [\n                    <jats:sup>68<\/jats:sup>\n                    Ga]-DOTATATE brain PET\/MRI. Lesions were classified as meningiomas and post-treatment change (PTC), using follow-up pathology and MRI as reference standard. Lesions were reclassified using the following methods: absolute maximum SUV threshold (SUV), SUV ratio (SUVR) to superior sagittal sinus (SSS) (SUVRsss), SUVR to the pituitary gland (SUVRpit), and SUVR to the normal brain parenchyma (SUVRnorm). Diagnostic performance of the four methods was compared using contingency tables and McNemar\u2019s test. Previously published pre-determined thresholds were assessed where applicable. The optimal thresholds for each method were identified using Youden\u2019s J statistics. 166 meningiomas and 41 PTC lesions were identified across 62 patients. SUV, SUVRsss, SUVRpit, and SUVRnorm of meningioma were significantly higher than those of PTC (P\u2009&lt;\u20090.0001). The optimal thresholds for SUV, SUVRsss, SUVRpit, and SUVRnorm were 4.7, 3.2, 0.3, and 62.6, respectively. At the optimal thresholds, SUV had the highest specificity (97.6%) and SUVRsss had the highest sensitivity (86.1%). An ROC analysis of SUV, SUVRsss, SUVRpit, and SUVRnorm revealed AUC of 0.932, 0.910, 0.915, and 0.800, respectively (P\u2009&lt;\u20090.0001). Developing a diagnostic threshold is key to wider clinical translation of [\n                    <jats:sup>68<\/jats:sup>\n                    Ga]-DOTATATE PET\/MRI in meningioma evaluation. We found that the SUVRsss method may have the most robust combination of sensitivity and specificity in the diagnosis of meningioma in the post-treatment setting, with the optimal threshold of 3.2. Future studies validating our findings in different patient populations are needed to continue optimizing the diagnostic performance of [\n                    <jats:sup>68<\/jats:sup>\n                    Ga]-DOTATATE PET\/MRI in meningioma patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial registration<\/jats:bold>\n                    : ClinicalTrials.gov Identifier: NCT04081701. Registered 9 September 2019.\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04081701\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04081701<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-13467-9","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T06:03:01Z","timestamp":1654236181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [68Ga]-DOTATATE PET\/MRI analysis in patients with meningioma"],"prefix":"10.1038","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04081701","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sean H.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Roytman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Madera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv S.","family":"Magge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Liechty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Ramakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Pannullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore H.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A.","family":"Karakatsanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eaton","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P. S.","family":"Knisely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Ivanidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"13467_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","volume":"19","author":"QT Ostrom","year":"2017","unstructured":"Ostrom, Q. T. et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010\u20132014. Neuro Oncol. 19, v1\u2013v88. https:\/\/doi.org\/10.1093\/neuonc\/nox158 (2017).","journal-title":"Neuro Oncol."},{"key":"13467_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3171\/2014.7.JNS131644","volume":"122","author":"L Rogers","year":"2015","unstructured":"Rogers, L. et al. Meningiomas: Knowledge base, treatment outcomes, and uncertainties. A RANO review. J. Neurosurg. 122, 4\u201323. https:\/\/doi.org\/10.3171\/2014.7.JNS131644 (2015).","journal-title":"J. Neurosurg."},{"key":"13467_CR3","doi-asserted-by":"publisher","first-page":"568079","DOI":"10.3389\/fonc.2020.568079","volume":"10","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Prognostic model that predicts benefits of adjuvant radiotherapy in patients with high grade meningioma. Front. Oncol. 10, 568079. https:\/\/doi.org\/10.3389\/fonc.2020.568079 (2020).","journal-title":"Front. Oncol."},{"key":"13467_CR4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jon.12632","volume":"29","author":"J Ivanidze","year":"2019","unstructured":"Ivanidze, J. et al. Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas. J. Neuroimaging 29, 650\u2013656. https:\/\/doi.org\/10.1111\/jon.12632 (2019).","journal-title":"J. Neuroimaging"},{"key":"13467_CR5","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.2967\/jnumed.117.191932","volume":"58","author":"WG Kunz","year":"2017","unstructured":"Kunz, W. G. et al. Improved detection of transosseous meningiomas using (68)Ga-DOTATATE PET\/CT compared with contrast-enhanced MRI. J. Nucl. Med. 58, 1580\u20131587. https:\/\/doi.org\/10.2967\/jnumed.117.191932 (2017).","journal-title":"J. Nucl. Med."},{"key":"13467_CR6","doi-asserted-by":"publisher","first-page":"9064","DOI":"10.1038\/s41598-021-87866-9","volume":"11","author":"HC Einhellig","year":"2021","unstructured":"Einhellig, H. C. et al. Comparison of diagnostic value of 68Ga-DOTATOC PET\/MRI and standalone MRI for the detection of intracranial meningiomas. Sci. Rep. 11, 9064. https:\/\/doi.org\/10.1038\/s41598-021-87866-9 (2021).","journal-title":"Sci. Rep."},{"key":"13467_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00259-009-1270-2","volume":"37","author":"F Nyuyki","year":"2010","unstructured":"Nyuyki, F. et al. Potential impact of 68Ga-DOTATOC PET\/CT on stereotactic radiotherapy planning of meningiomas. Eur. J. Nucl. Med. Mol. Imaging 37, 310\u2013318. https:\/\/doi.org\/10.1007\/s00259-009-1270-2 (2010).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"13467_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi, J. C. et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27, 273\u2013282. https:\/\/doi.org\/10.1007\/s002590050034 (2000).","journal-title":"Eur. J. Nucl. Med."},{"key":"13467_CR9","first-page":"13185","volume":"8","author":"CB Silva","year":"2015","unstructured":"Silva, C. B. et al. Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. Int. J. Clin. Exp. Pathol. 8, 13185\u201313192 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"13467_CR10","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2967\/jnumed.106.035667","volume":"48","author":"M Gabriel","year":"2007","unstructured":"Gabriel, M. et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 48, 508. https:\/\/doi.org\/10.2967\/jnumed.106.035667 (2007).","journal-title":"J. Nucl. Med."},{"key":"13467_CR11","doi-asserted-by":"publisher","first-page":"vdab012","DOI":"10.1093\/noajnl\/vdab012","volume":"3","author":"SS Mahase","year":"2021","unstructured":"Mahase, S. S. et al. [(68)Ga]-DOTATATE PET\/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas. Neurooncol. Adv. 3, vdab012. https:\/\/doi.org\/10.1093\/noajnl\/vdab012 (2021).","journal-title":"Neurooncol. Adv."},{"key":"13467_CR12","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1148\/rg.352140164","volume":"35","author":"MS Hofman","year":"2015","unstructured":"Hofman, M. S., Lau, W. F. E. & Hicks, R. J. Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: Clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35, 500\u2013516. https:\/\/doi.org\/10.1148\/rg.352140164 (2015).","journal-title":"Radiographics"},{"key":"13467_CR13","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00259-012-2155-3","volume":"39","author":"A Afshar-Oromieh","year":"2012","unstructured":"Afshar-Oromieh, A. et al. Detection of cranial meningiomas: Comparison of 68Ga-DOTATOC PET\/CT and contrast-enhanced MRI. Eur. J. Nucl. Med. Mol. Imaging 39, 1409\u20131415. https:\/\/doi.org\/10.1007\/s00259-012-2155-3 (2012).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"13467_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/wjnm.WJNM_39_18","volume":"18","author":"RV Parghane","year":"2019","unstructured":"Parghane, R. V., Talole, S. & Basu, S. Prevalence of hitherto unknown brain meningioma detected on (68)Ga-DOTATATE positron-emission tomography\/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of (177)Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors. World J. Nucl. Med. 18, 160\u2013170. https:\/\/doi.org\/10.4103\/wjnm.WJNM_39_18 (2019).","journal-title":"World J. Nucl. Med."},{"key":"13467_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4103\/ijnm.IJNM_98_19","volume":"34","author":"MJ Pelak","year":"2019","unstructured":"Pelak, M. J. & d\u2019Amico, A. The prognostic value of pretreatment gallium-68 DOTATATE positron emission tomography\/computed tomography in irradiated non-benign meningioma. Indian J. Nucl. Med. 34, 278\u2013283. https:\/\/doi.org\/10.4103\/ijnm.IJNM_98_19 (2019).","journal-title":"Indian J. Nucl. Med."},{"key":"13467_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10654-015-0101-y","volume":"31","author":"CO Schmidt","year":"2016","unstructured":"Schmidt, C. O. et al. Impact of whole-body MRI in a general population study. Eur. J. Epidemiol. 31, 31\u201339. https:\/\/doi.org\/10.1007\/s10654-015-0101-y (2016).","journal-title":"Eur. J. Epidemiol."},{"key":"13467_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2967\/jnumed.114.149120","volume":"56","author":"W Rachinger","year":"2015","unstructured":"Rachinger, W. et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J. Nucl. Med. 56, 347\u2013353. https:\/\/doi.org\/10.2967\/jnumed.114.149120 (2015).","journal-title":"J. Nucl. Med."},{"key":"13467_CR18","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/neuonc\/now060","volume":"18","author":"K Seystahl","year":"2016","unstructured":"Seystahl, K. et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: Benefit linked to 68Ga-DOTATATE\/-TOC uptake. Neuro Oncol. 18, 1538\u20131547. https:\/\/doi.org\/10.1093\/neuonc\/now060 (2016).","journal-title":"Neuro Oncol."},{"key":"13467_CR19","doi-asserted-by":"publisher","first-page":"e210067","DOI":"10.1148\/rycan.210067","volume":"4","author":"J Ivanidze","year":"2022","unstructured":"Ivanidze, J. et al. Dynamic (68)Ga-DOTATATE PET\/MRI in the diagnosis and management of intracranial meningiomas. Radiol. Imaging Cancer. 4, e210067. https:\/\/doi.org\/10.1148\/rycan.210067 (2022).","journal-title":"Radiol. Imaging Cancer."},{"key":"13467_CR20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/neuonc\/now001","volume":"18","author":"M Sommerauer","year":"2016","unstructured":"Sommerauer, M. et al. 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?. Neuro Oncol. 18, 1021\u20131027. https:\/\/doi.org\/10.1093\/neuonc\/now001 (2016).","journal-title":"Neuro Oncol."},{"key":"13467_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.prp.2010.09.001","volume":"207","author":"K Mocker","year":"2011","unstructured":"Mocker, K. et al. Multiple meningioma with different grades of malignancy: Case report with genetic analysis applying single-nucleotide polymorphism array and classical cytogenetics. Pathol. Res. Pract. 207, 67\u201372. https:\/\/doi.org\/10.1016\/j.prp.2010.09.001 (2011).","journal-title":"Pathol. Res. Pract."},{"key":"13467_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0090-3019(89)90048-7","volume":"31","author":"G Butti","year":"1989","unstructured":"Butti, G., Assietti, R., Casalone, R. & Paoletti, P. Multiple meningiomas: A clinical, surgical, and cytogenetic analysis. Surg. Neurol. 31, 255\u2013260. https:\/\/doi.org\/10.1016\/0090-3019(89)90048-7 (1989).","journal-title":"Surg. Neurol."},{"key":"13467_CR23","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1200\/jco.2003.07.156","volume":"21","author":"A Maillo","year":"2003","unstructured":"Maillo, A. et al. New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology. J. Clin. Oncol. 21, 3285\u20133295. https:\/\/doi.org\/10.1200\/jco.2003.07.156 (2003).","journal-title":"J. Clin. Oncol."},{"key":"13467_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab150","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner, R. et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noab150 (2021).","journal-title":"Neuro Oncol."},{"key":"13467_CR25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ijrobp.2005.12.006","volume":"65","author":"S Milker-Zabel","year":"2006","unstructured":"Milker-Zabel, S. et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int. J. Radiat. Oncol. Biol. Phys. 65, 222\u2013227. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.12.006 (2006).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"13467_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijrobp.2012.03.021","volume":"85","author":"R Graf","year":"2013","unstructured":"Graf, R. et al. Contribution of 68Ga-DOTATOC PET\/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 85, 68\u201373. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.03.021 (2013).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"13467_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5414\/npp27334","volume":"27","author":"A Durand","year":"2008","unstructured":"Durand, A. et al. Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: Relation to grades or histotypes. Clin. Neuropathol. 27, 334\u2013345. https:\/\/doi.org\/10.5414\/npp27334 (2008).","journal-title":"Clin. Neuropathol."},{"issue":"Suppl 2","key":"13467_CR28","first-page":"S219","volume":"31","author":"EP Krenning","year":"1999","unstructured":"Krenning, E. P. et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital. J. Gastroenterol. Hepatol. 31(Suppl 2), S219\u2013S223 (1999).","journal-title":"Ital. J. Gastroenterol. Hepatol."},{"key":"13467_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clinimag.2020.04.026","volume":"66","author":"M Roytman","year":"2020","unstructured":"Roytman, M. et al. Somatostatin receptor-2 negative meningioma: Pathologic correlation and imaging implications. Clin. Imaging 66, 18\u201322. https:\/\/doi.org\/10.1016\/j.clinimag.2020.04.026 (2020).","journal-title":"Clin. Imaging"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13467-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13467-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13467-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:48:44Z","timestamp":1669330124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13467-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["13467"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-13467-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"19 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9256"}}